The largest health area in Andalusia, which covers the southern part of the province of Seville, has developed its particular mechanism to go from its primary care centers and to Valme University Hospital the new corporate program of vaccination against Respiratory Syncytial Virus (RSV).
Andalusia, which has one of the most advanced vaccination schedules in the national territory as a sign of its commitment to health prevention, administered for the first time since September 25 the Nirsevimab monoclonal antibody against the RSV.
RSV is responsible for a very high burden of childhood disease worldwide, causing most cases of bronchiolitis in infants. This is why it is the main person responsible for primary care visits, emergencies and hospitalizations for this disease in children less than 6 months of age.
The target population that will receive a dose of Nirsevimab during the autumn-winter campaign of 2023-2024 in Andalusia is composed of all those born from October 1, 2023 to March 31, 2024, infants under 6 months the age; in addition to those under one year of age with a history of prematurity less than 35 weeks of gestation and also those under two years of age with various high-risk conditions.
Regarding the appointment for immunization against Respiratory Syncytial Virus, the health centers themselves, such as Valme, will contact the population to set a day and time for the inoculation dose of minors.
For this, the primary nurses in Child Health care are promoting the active recruitment of children born from April 1 to September 30 and children with a history of prematurity of less than 35 weeks. one year old on these dates. Parents whose babies belong to these criteria can also voluntarily access health centers to make an appointment.
